Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ANIX NASDAQ:ICCC NASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.76-5.3%$4.70$3.35▼$17.94$82.03M4.5240,688 shs94,934 shsANIXAnixa Biosciences$2.51-1.6%$2.80$2.44▼$5.46$84.16M0.59140,971 shs58,521 shsICCCImmuCell$9.88+0.9%$8.07$4.52▼$10.75$89.41M0.5522,955 shs10,336 shsJSPRJasper Therapeutics$0.50-9.5%$0.91$0.43▼$7.19$13.94M3.01575,402 shs1.36 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-0.50%-5.48%-27.29%-29.61%-64.33%ANIXAnixa Biosciences-5.56%-6.59%-18.79%-12.37%-11.76%ICCCImmuCell+1.24%-6.76%+12.14%+51.55%+44.40%JSPRJasper Therapeutics+3.20%-39.59%-40.74%-61.18%-89.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.76-5.3%$4.70$3.35▼$17.94$82.03M4.5240,688 shs94,934 shsANIXAnixa Biosciences$2.51-1.6%$2.80$2.44▼$5.46$84.16M0.59140,971 shs58,521 shsICCCImmuCell$9.88+0.9%$8.07$4.52▼$10.75$89.41M0.5522,955 shs10,336 shsJSPRJasper Therapeutics$0.50-9.5%$0.91$0.43▼$7.19$13.94M3.01575,402 shs1.36 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-0.50%-5.48%-27.29%-29.61%-64.33%ANIXAnixa Biosciences-5.56%-6.59%-18.79%-12.37%-11.76%ICCCImmuCell+1.24%-6.76%+12.14%+51.55%+44.40%JSPRJasper Therapeutics+3.20%-39.59%-40.74%-61.18%-89.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70422.55% UpsideANIXAnixa Biosciences 2.25Hold$8.50237.30% UpsideICCCImmuCell 1.00SellN/AN/AJSPRJasper Therapeutics 2.33Hold$13.142,474.51% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, ICCC, ANIX, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026JSPRJasper Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetSector Perform$4.00 ➝ $3.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026JSPRJasper Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/6/2026ICCCImmuCell Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/AANIXAnixa Biosciences$210K402.36N/AN/A$0.42 per share6.00ICCCImmuCell$27.64M3.20$0.19 per share50.16$2.99 per share3.27JSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/AANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%6/3/2026 (Estimated)ICCCImmuCell-$1.04M-$0.06N/AN/AN/A-1.82%-1.88%-1.22%8/13/2026 (Estimated)JSPRJasper Therapeutics-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)Latest JSPR, ICCC, ANIX, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/14/2026Q1 2026ICCCImmuCell$0.05$0.21+$0.16$0.21$5.40 million$10.36 million5/14/2026Q1 2026JSPRJasper Therapeutics-$0.46-$0.38+$0.08-$0.04N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A3/30/2026Q4 2025JSPRJasper Therapeutics-$0.79-$0.3250+$0.4650-$0.32N/AN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06ANIXAnixa BiosciencesN/A12.1812.18ICCCImmuCell0.244.822.60JSPRJasper TherapeuticsN/A2.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AANIXAnixa Biosciences29.13%ICCCImmuCell13.47%JSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AANIXAnixa Biosciences26.40%ICCCImmuCell5.70%JSPRJasper Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/AANIXAnixa Biosciences533.53 million24.68 millionOptionableICCCImmuCell709.05 million8.53 millionNot OptionableJSPRJasper Therapeutics2028.00 million26.71 millionOptionableJSPR, ICCC, ANIX, and AARD HeadlinesRecent News About These CompaniesBears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now3 hours ago | zacks.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)June 2 at 5:52 PM | theglobeandmail.comJasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueJune 1 at 8:00 AM | globenewswire.comJasper Therapeutics Announces Board Resignation and Committee ChangeMay 21, 2026 | tipranks.comJasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | globenewswire.comJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | markets.businessinsider.comJasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | globenewswire.comJasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceFebruary 24, 2026 | globenewswire.comJasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria TranscriptJanuary 8, 2026 | seekingalpha.comJasper Therapeutics, Inc.: Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical GrowthJanuary 8, 2026 | finanznachrichten.deJasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous UrticariaJanuary 8, 2026 | globenewswire.comJasper Therapeutics stock rises after leadership changesJanuary 7, 2026 | za.investing.comJasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical GrowthJanuary 7, 2026 | globenewswire.comJasper stock jumps after positive asthma study resultsDecember 2, 2025 | za.investing.comJasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data TranscriptDecember 2, 2025 | seekingalpha.comJasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal InvestigationDecember 2, 2025 | globenewswire.comJasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study InvestigationDecember 1, 2025 | globenewswire.comBragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNovember 22, 2025 | globenewswire.comCompanies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite RiskyNovember 20, 2025 | uk.finance.yahoo.comJSPR DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPRNovember 18, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, ICCC, ANIX, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$3.76 -0.21 (-5.29%) As of 02:28 PM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Anixa Biosciences NASDAQ:ANIX$2.51 -0.04 (-1.57%) As of 02:04 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.ImmuCell NASDAQ:ICCC$9.88 +0.09 (+0.92%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Jasper Therapeutics NASDAQ:JSPR$0.50 -0.05 (-9.49%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
